Mustang Bio is a clinical-stage biopharmaceutical company focused on cell and gene therapies for hematologic cancers, solid tumors and rare genetic diseases. Co.'s pipeline is focused in three main areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. Co. is developing CAR T therapies for hematologic malignancies in partnership with City of Hope National Medical Center (COH) targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). Co. is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103) and PSCA (MB-105). We show 25 historical shares outstanding datapoints in our MBIO shares outstanding history coverage, used to compute MBIO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MBIO market cap history over the course of time is important for investors
interested in comparing MBIO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MBIO versus a peer is one thing; comparing
MBIO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MBIO can fluctuate over the course of history.
With this page we aim to empower investors researching MBIO by allowing them to research the MBIO market cap history. |
Free MBIO Email Alerts:
Video: The Importance of Market Cap
